P024 Therapeutic potential of the human amniotic fluid mesenchymal stem cells/stroma cells secreted molecules in a mice model of colitis
M. Gazouli*1, E. Legaki1, M. Roubelakis1, A. Lazaris2, G. Karamanolis3, E. Marinos1, G. Theodoropoulos4
1School of Medicine, University of Athens, Biology, Athens, Greece, 2School of Medicine, University of Athens, Pathology, Athens, Greece, 3School of Medicine, University of Athens, Gastroenterology, Athens, Greece, 4School of Medicine, University of Athens, Surgery, Athens, Greece
Background
Inflammatory bowel diseases (IBDs) are the result of pathological immune responses to environmental factors/microbial antigens to a genetically predisposed individual. Mainly because of their trophic properties, there is mounting interest in the therapeutic potential of human mesenchymal stem cells (hMSCs). The aim of the study was to test the potential of the secreted molecules derived from a distinct population of second trimester amniotic fluid mesenchymal stem/stromal cells, termed as human spindle-shaped mesenchymal stem cells (SS-AF-MSCs), as a novel approach for IBD MSC-based therapy.
Methods
Colitis was induced in approximately 8-week-old NOD/SCID mice by daily oral administration of dextran sulphate sodium (DSS) (3% w/v in tap water) for 5 days. The colitis evolution was evaluated by daily monitoring of body weight, stool consistency, and bleeding. Conditioned media (CM) derived from ss-AF-MSCs cells were collected, concentrated, and then delivered intraperitoneally. Histopathological analysis was performed, and inflammatory cytokine levels were determined
Results
Administration of CM derived from ss-AF-MSCs cells reduced the severity of colitis in mice. TGFb1 protein levels were increased in the mice received CM, whereas TNFa and MMP2 protein levels were decreased. Accordingly, IL-10 (anti-inflammatory) mRNA levels were significantly increased in mice that received CM, whereas TNFa and IL-1b mRNA levels were decreased.
Conclusion
Our results demonstrated that CM derived from ss-AF-MSCs cells is able to ameliorate DSS-induced colitis in immunodeficient colits mouse model, and it is a promising therapeutic approach for IBD treatment.